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OBJECTIVES The aim of this study was to evaluate a possible relationship between homocysteine levels on
admission and late outcome after successful percutaneous coronary intervention (PCI).
BACKGROUND Increasing evidence suggests that mild to moderate elevation of total plasma homocysteine is
a graded and potentially modifiable risk factor for cardiovascular disease and death that
appears to be largely independent of other traditional risk factors.
METHODS A total of 549 patients were included after successful PCI of at least one coronary stenosis
(50%). End points were cardiac death, nonfatal myocardial infarction (MI), target lesion
revascularization (TLR), and a composite of major adverse cardiac events (MACE). The
relationship between homocysteine levels and study endpoints was assessed.
RESULTS After a median ( SD) follow-up of 58 20 weeks, 6 patients died of cardiac death, 14 were
diagnosed with a new MI, and 71 underwent repeat TLR. A graded relationship between
homocysteine levels (quartiles) and freedom from MACE was found (p  0.01). Homo-
cysteine levels ( SD) were associated with cardiac death (14.9  1.7 mol/l vs. 9.6 
4.3 mol/l, p 0.005), TLR (10.7 4.4 mol/l vs. 9.5 4.3 mol/l, p 0.05), and overall
MACE (11.0  4.4 mol/l vs. 9.4  4.3 mol/l, p  0.005). These findings remained
unchanged after adjustment for potential confounders.
CONCLUSIONS Plasma homocysteine is an independent predictor of mortality, nonfatal MI, TLR, and overall
adverse late outcome after successful coronary angioplasty. (J Am Coll Cardiol 2002;40:
1769–76) © 2002 by the American College of Cardiology Foundation
Total plasma homocysteine has emerged as an important
and potentially modifiable cardiovascular risk factor which
correlates with the severity of coronary and carotid artery
disease (1–5). Elevated homocysteine levels predict mortal-
ity, the occurrence of late cardiac events in patients with
established coronary atherosclerosis, and the incidence of
cerebrovascular accidents in middle-aged men and elderly
patients (6–9). There are also some indications linking
homocysteine levels with late lumen loss after percutaneous
coronary intervention (PCI) or after carotid endarterectomy
(10–13), whereby the exact mechanism is not clear but may
be linked to homocysteine-induced myointimal hyperplasia,
connective tissue proliferation, and endothelial dysfunction
(12–15). However, in the light of some contradictory
findings in prospective studies, this possible pathophysio-
logic mechanism between homocysteine levels and resteno-
sis remains uncertain (16–18). Furthermore, there is grow-
ing belief that atherosclerotic disease itself may elevate
homocysteine levels and that this emerging cardiovascular
risk factor is only a silent bystander and should be consid-
ered a marker rather than a true risk factor (19). Encouraged
by our previous findings of an association between angio-
graphic restenosis and homocysteine levels, but with clinical
end points not reaching statistical significance (11), we now
report in an extension study with more than twice as many
patients, the effect of homocysteine levels on late clinical
outcome after successful PCI, with special regard to the
traditional cardiovascular risk factors.
METHODS
This was a prospective study enrolling 549 consecutive
patients having undergone successful PCI of at least one
native coronary stenosis (50%). The study population
included a subgroup of 205 patients scheduled for six
months follow-up angiography with quantitative results
published elsewhere (11). Patients were not enrolled if they
had recent myocardial infarction (MI) (2 weeks), signifi-
cant left main disease, were undergoing PCI of a bypassed
native vessel with patent graft, had impaired renal function
(serum creatinine 1.8 mg/dl), or were taking multivita-
mins. Fasting homocysteine levels were measured on admis-
sion using a rapid high-performance liquid chromato-
graphic assay (20). Percutaneous coronary intervention was
performed according to standard techniques, with success
defined as residual diameter stenosis 50% with Throm-
bolysis in Myocardial Infarction flow grade 3 pattern.
Angiographic evaluation was performed using an automated
edge-detection system (Philips Integris-BH-3000, Version 2,
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if online or Philips View-Station-CDM-3500, Version 2, if
offline; Philips, Best, The Netherlands) with techniques
described elsewhere (11). Patients were recruited between
September 1997 and May 1998. Written informed consent
was obtained from each patient. This study was approved by
the Institutional Review Board of the University Hospital in
Bern, Switzerland.
Follow-up and study end points. Resting electrocardio-
gram and noninvasive stress test were performed at one-year
follow-up, or earlier if symptoms recurred. Adverse events
were defined as: 1) death from any cause; 2) cardiac death,
defined as sudden, unexplained death, or death related to
MI; 3) nonfatal MI, defined as new Q waves (40 ms;
0.2 mV) in two or more contiguous electrocardiographic
leads; 4) ischemia-driven target lesion revascularization
(TLR) with angiographic restenosis 50%; and 5) a com-
posite of major adverse cardiac events (MACE) defined as
any of the above cardiac events. Patients who had more than
one lesion treated by PCI were defined as having TLR if at
least one dilated lesion fulfilled revascularization criteria.
Finally, patients with more than one event had only the first
occurring event computed for overall MACE determina-
tion.
Statistical analysis. A sample size of 540 patients (135
patients in each homocysteine quartile) was calculated to
detect a 15% absolute difference in MACE rates between
the highest and lowest homocysteine quartiles. Assuming a
15% dropout rate, the planned sample size would yield 460
patients with complete follow-up and give the study a
statistical power of 0.90 at a significance level of 0.05.
Plasma homocysteine levels were not normally distributed
(skewness: 1.61) and, therefore, were log-transformed be-
fore analysis. Results were shown in natural units. Plasma
homocysteine was first considered as a continuous value and
then as a categorical variable divided into quartiles to
examine the between-quartile relationship with end points.
Continuous variables are reported as mean  SD. Categor-
ical variables are reported as counts (percentages) and
compared between groups using a chi-square test. Contin-
uous variables were examined by a two-tailed t test or by the
Mann-Whitney U test if not normally distributed. The
Spearman rank correlation coefficient was used to estimate
the correlation between homocysteine levels and different
continuous variables. Baseline characteristics were compared
over homocysteine quartiles with a chi-square test or Fisher
exact test when appropriate for categorical variables, and a
one-way analysis of variance was used for continuous vari-
ables. The Bonferroni t test was use for multiple compari-
sons between continuous variables and homocysteine quar-
tiles. Freedom from MACE was analyzed by means of
Kaplan-Meier curves, with differences between homocys-
teine quartiles assessed with the Mantel-Cox log-rank test.
Cox proportional-hazards regression models were used to
examine the relationship between plasma homocysteine and
the different end points, after adjustment for multiple
clinical and angiographic covariates significantly associated
with each end point in univariate analysis. A two-sided 5%
level of significance was considered significant for all statis-
tical tests. Data were prospectively collected and analyzed
using StatView Version 4.5 (SAS Institute, Cary, North
Carolina).
RESULTS
A total of 549 patients were consecutively included after
successful PCI of at least one coronary stenosis (50%),
with a total of 732 successfully treated lesions. Of the
patients, 45 did not complete full follow-up criteria, 41
refused noninvasive stress testing, and 4 with proven isch-
emia refused re-angiography. This left a total of 504
patients (91.8%) with complete one-year follow-up. In
terms of baseline clinical, laboratory, and angiographic
criteria, the 45 patients without complete follow-up did not
significantly differ from the remaining population.
Clinical and angiographic characteristics. The study
population had a mean age of 62 years with an overall
proportion of women of 20% (Table 1). Patients in the
fourth homocysteine quartile were significantly older (64
years) and less likely to be women (14%). The highest
proportion of women (27%) was found in the first quartile.
The distribution of cardiovascular risk factors was similar
throughout all quartiles. The severity of the coronary artery
disease (as measured by the number of vessels with at least
one significant stenosis [50%]) increased steadily over the
quartiles. Furthermore, there were significantly fewer pa-
tients with a history of MI in the first quartile. Patients in
the first quartile had also significantly lower serum creati-
nine and higher high-density lipoprotein (HDL) cholesterol
levels. The mean ( SD) study homocysteine level was
10.1 4.8 mol/l, 1.1 mol/l lower in women than in men
(9.2  4.9 mol/l vs. 10.3  4.6 mol/l, p  0.05) and
increased 0.3 mol/l for each additional 10 years of age
(rs  0.11, p  0.01). Overall, homocysteine levels were
significantly correlated with serum creatinine (rs  0.22,
p 0.0001) and HDL cholesterol (rs0.15, p 0.001).
The mean ( SD) homocysteine level was also 1.1 mol/l
higher in patients with previous MI than in those without
such a history (10.6 5.0 mol/l vs. 9.5 4.6 mol/l, p
0.01). Finally, angiographic characteristics were comparable
among the homocysteine quartiles (Table 2).
Abbreviations and Acronyms
CI  confidence interval
HDL  high-density lipoprotein
LDL  low-density lipoprotein
MACE  major adverse cardiac events
MI  myocardial infarction
PCI  percutaneous coronary intervention
RR  relative risk
TLR  target lesion revascularization
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Study end points. After a mean ( SD) follow-up of 58
20 weeks, 8 patients (1.6%) had died, 6 of them from
cardiac origin (1.2%). All but one death and all six cardiac
deaths had homocysteine levels in the fourth quartile (p 
0.05) (Table 3). Patients whose death was of cardiac origin
had homocysteine levels 5.3 mol/l higher than the remain-
ing study population (p  0.005) (Table 4). During follow-
up, 14 patients (2.8%) had presented with a new nonfatal
MI, and 11 of these patients had homocysteine levels in the
upper two quartiles (p  0.14) (Table 3). Patients with
nonfatal MI had homocysteine levels 1.6 mol/l higher
than the remaining study population (p  0.18) (Table 4).
Over the course of the study, 71 patients (14.1%) had
undergone TLR, 8.0% in the lowest and 18.9% in the
highest homocysteine quartile (p  0.05) (Table 3). Those
patients had homocysteine levels 1.2 mol/l higher than the
remaining study population (p  0.05) (Table 4). Finally,
there was a graded relationship between homocysteine levels
and the incidence of MACE. This composite end point was
reached by 75 patients (14.9%), 8.0% in the lowest and
22.0% in the highest homocysteine quartile (p  0.01)
(Table 3). This relationship was also evident in the Kaplan-
Meier curves for freedom from MACE at one year, with
92.0% of patients in the first homocysteine quartile free of
any cardiac event, 88.6% in the second quartile, 82.2% in
the third quartile, and 78.0% in the fourth quartile (Fig. 1),
a relative risk (RR) increase between extreme quartiles of 2.8
(95% confidence interval [CI]  1.34 to 5.67) (Fig. 2).
These findings were reproduced in subgroups of patients
stratified according to the traditional cardiovascular risk
factors (gender, diabetes mellitus, hypertension, hypercho-
lesterolemia, and smoking) (Fig. 2). The strongest RR
increase between the first and fourth quartile was found in
men, smokers, and hypercholesterolemic patients (RR 
3.00, 95% CI  1.27 to 7.12; RR  3.50, 95% CI  0.73
to 9.62; and RR  2.45, 95% CI  1.13 to 5.30,
respectively). Interestingly, even though the incidence of
MACE was independent of levels of cholesterol, HDL
cholesterol, low-density lipoprotein (LDL) cholesterol, and
triglycerides (p  0.93, p  0.35, p  0.31, and p  0.45,
respectively), there was a substantial RR increase between
the first and the fourth homocysteine quartile in patients
with LDL cholesterol in the upper 50th percentile (RR 
5.08, 95% CI  1.49 to 17.33) as opposed to (RR  1.32,
95% CI 0.52 to 3.36) LDL cholesterol levels in the lower
50th percentile.
Table 1. Patients’ Characteristics*
Homocysteine Quartile
p Value
1 2 3 4
<6.4 mol/l
(n  136)
6.4–8.6 mol/l
(n  136)
8.7–12.0 mol/l
(n  139)
>12.0 mol/l
(n  138)
Men/women (%) 73/27† 81/19 81/19 86/14 0.07
Age (yrs) 61  11† 60  11† 62  10 64  12 0.06
Smoker (%)§ 43 49 43 47 0.64
Diabetes mellitus (%)¶ 22 28 27 22 0.45
Hypertension (%) 63 58 67 56 0.21
Hypercholesterolemia (%)# 85 83 80 86 0.51
Previous MI (%) within the last
6 months (%)
41 59‡ 58‡ 60‡ 0.008
28 32 32 36 0.62
Previous PTCA (%) 26 29 32 31 0.58
Previous CABG (%) 9 10 11 15 0.35
Severity: I to III vessel disease (%)** I (43) II (35) III (22)† I (46) II (32) III (22)† I (33) II (33) III (34) I (27) II (40) III (33) 0.02
Laboratory findings
Hb A1c (%) 5.9  1.0 6.0  1.2 5.9  1.0 5.9  1.0 0.81
Creatinine (mg/dl) 0.98  0.15 1.01  0.17† 1.06  0.21‡ 1.07  0.21‡  0.0001
Homocysteine (mol/l) 5.3  1.0 7.4  0.7 10.5  1.2 16.9  4.5
Cholesterol (mg/dl) 211  44 220  41 209  52 212  42 0.23
HDL cholesterol (mg/dl) 48  14† 46  12 44  12 43  12 0.03
LDL cholesterol (mg/dl) 128  36 134  36 127  49 131  37 0.57
Triglycerides (mg/dl) 174  108 188  122 187  147 180  123 0.82
Discharge therapy (%)
Statins 60 52 52 59 0.54
Beta-blockers 68 57 64 59 0.29
ACE inhibitors 28 35 37 38 0.32
Aspirin 96 96 96 96 0.99
ADP inhibitors 55 57 56 59 0.89
*Continuous variables: mean SD. Baseline characteristics were compared over homocysteine quartiles with a chi-square test for categorical variables and using a one-way analysis
of variance (ANOVA) for continuous variables. The Bonferroni t test was used for multiple-comparisons between continuous variables and homocysteine quartiles. Conversion
factors between conventional and SI units: Creatinine 88.4  mg/dl  mol/l; Cholesterol (total, HDL, LDL): 0.0259  mg/dl  mmol/l; Triglycerides: 0.0113  mg/dl 
mmol/l. †p  0.05 vs. 4th quartile; ‡p  0.005 vs. 1st quartile. §Smoker: current or discontinued during the last six months. Hypertension: 140/90 mm Hg or current
antihypertensive therapy. ¶Diabetes mellitus: Hb A1c  6.2%, current insulin or oral hypoglycemic therapy. #Hypercholesterolemia: cholesterol  200 mg/dl or current
lipid-lowering therapy. **I: 1-vessel disease; II: 2-vessel disease; III: 3-vessel disease; 1 lesion, 50% diameter stenosis per vessel.
ACE  angiotensin-converting enzyme; ADP  adenosine diphosphate; CABG  coronary artery bypass graft; Hb A1c  glycosylated hemoglobin; HDL  high-density
lipoprotein; LDL  low-density lipoprotein; MI  myocardial infarction; PTCA  percutaneous transluminal coronary angioplasty.
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Additional covariates. Besides homocysteine levels, four
other factors were univariate risk predictors for MACE:
diabetes mellitus treated with oral hypoglycemics, treatment
of restenotic lesions, vessel diameter, and post-PCI residual
minimal luminal diameter (Table 5). After multivariate Cox
regression analysis, only homocysteine levels (multivariate,
p  0.005), diabetes mellitus treated with oral hypoglyce-
mics (multivariate, p  0.004), and treatment of restenotic
lesions (multivariate, p  0.006) retained statistical signif-
icance. The same factors were also significantly associated
with the need for TLR (Table 5), with similar results after
multivariate analysis (homocysteine levels [multivariate, p
0.02], diabetes mellitus treated with oral hypoglycemics
[multivariate, p  0.007], and treatment of restenotic
lesions [multivariate, p  0.003]). With regard to nonfatal
MI, homocysteine quartiles and the number of diseased
coronary arteries per patient were univariate risk predictors
(Table 5), but only homocysteine quartiles retained statis-
tical significance after multivariate analysis (multivariate,
p  0.04). Finally, death rates were dependent on homo-
cysteine levels, the number of diseased coronary arteries per
patient, and left ventricular ejection fraction (Table 5). After
multivariate analysis, only left ventricular ejection fraction
(multivariate, p  0.046) and homocysteine levels (multi-
variate, p  0.008) remained independent predictors of
cardiac death, while only plasma homocysteine (multivari-
ate, p  0.009) retained statistical significance for overall
death. Similar results were obtained when patients in the
two lower homocysteine quartiles were compared with
patients in the two higher quartiles.
Table 2. Lesion Characteristics and Treatment Options*
Homocysteine Quartile
p Value
1 2 3 4
<6.4 mol/l
(n  182)
6.4–8.6 mol/l
(n  180)
8.7–12.0 mol/l
(n  185)
>12.0 mol/l
(n  185)
Lesion location (%)
LAD 43 39 44 38 0.47
Circumflex 25 27 29 29 0.81
RCA 32 34 27 33 0.57
Restenotic lesions (%) 4.9 4.4 5.4 4.3 0.88
Treatment options (%)
Stents 56 58 55 57 0.73
Glycoprotein IIb/IIIa inhibitors 12 13 14 11 0.69
Reference vessel diameter (mm)
Before angioplasty 2.83  0.66 2.81  0.66 2.71  0.67 2.80  0.69 0.53
After angioplasty 3.02  0.63 3.01  0.65 2.91  0.61 3.06  0.66 0.66
Minimal luminal diameter (mm)
Before angioplasty 0.94  0.50 0.88  0.48 0.88  0.44 0.90  0.45 0.39
After angioplasty 2.26  0.59 2.31  0.61 2.24  0.59 2.35  0.58 0.47
Percent diameter stenosis (%)
Before angioplasty 67.0  14.9 68.6  15.8 67.5  15.3 67.7  14.8 0.72
After angioplasty 25.0  10.9 23.3  9.6 23.3  10.5 23.1  11.0 0.37
Lesion length (mm) 12.4  6.3 12.9  7.2 12.5  7.6 12.7  7.5 0.84
Number of treated lesions/patient 1.34  0.59 1.32  0.63 1.33  0.63 1.34  0.55 0.89
*Continuous variables are mean  SD. Lesion characteristics and treatment options were compared over homocysteine quartiles with a chi-square test for categorical variables
and using a one-way analysis of variance for continuous variables.
LAD  left anterior descending coronary artery; RCA  right coronary artery.
Table 3. Adverse Events at One-Year Follow-Up*
Adverse Events According to Homocysteine Quartile
p Value
1
(n  125)
2
(n  123)
3
(n  129)
4
(n  127)
Death (from any cause) (%) 0.0† 0.0† 0.8‡ 5.5 0.008
MACE (%)
Target lesion revascularization 8.0‡ 11.4 17.8§ 18.9 0.03
Nonfatal myocardial infarction 1.6 0.8‡ 3.1 5.5 0.14
Cardiac death 0.0† 0.0† 0.0† 4.7 0.03
Any cardiac event 8.0 11.4‡ 17.8§ 22.0 0.01
*Continuous variables: mean  SD. Adverse events were compared over homocysteine quartiles with a chi-square test. Because
of an absence of death in patients with homocysteine levels in the two lower homocysteine quartiles, death-related events were
computed comparing the 1st and 2nd homocysteine quartile with the 3rd and 4th quartile using the Fisher exact test. Fisher exact
test was also used for multiple comparisons between homocysteine quartiles when appropriate (death, cardiac death, nonfatal
myocardial infarction). †p  0.01 vs. 4th quartile; ‡p  0.05 vs. 4th quartile. §p  0.05 vs. 1st quartile; p  0.005 vs. 4th
quartile.
MACE  major adverse cardiac events.
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DISCUSSION
Elevated homocysteine levels have been shown to predict
mortality, the occurrence of late cardiac events in patients
with established coronary atherosclerosis, and the incidence
of cerebrovascular accidents (6–9). This study now provides
the first prospective evidence that homocysteine levels also
predict long-term outcome after PCI. Plasma homocysteine
is not only a significant predictor of TLR but also of
mortality, nonfatal MI, and overall MACE after successful
PCI. Furthermore, this observed association appeared to be
Figure 1. Kaplan-Meier curves for freedom from major adverse cardiac
events according to homocysteine quartiles. There is a strong dose-
response relationship between homocysteine quartiles and the incidence of
major adverse cardiac events, with 92.0% of patients in the first homocys-
teine quartile free of any cardiac event, 88.6% in the second quartile, 82.2%
in the third quartile, and 78.0% in the fourth quartile (p  0.05), a relative
risk increase between extreme quartiles of 2.8 (95% confidence interval 
1.34 to 5.67).
Figure 2. Relative risk of major adverse cardiac events according to homocysteine quartiles among total study population and subgroups of patients stratified
according to the traditional cardiovascular risk factors. Squares indicates the relative risk (RR) of major adverse cardiac events for patients in the second,
third, and fourth homocysteine quartile compared with patients in the first quartile; size of square is proportional to number of patients; and horizontal
line indicates 95% confidence interval (CI); RRs are displayed on logarithmic scale. The strongest RR increase between the first and fourth quartile was
found in men, smokers, and hypercholesterolemic patients (RR  3.00, 95% CI  1.27 to 7.12; RR  3.50, 95% CI  0.73 to 9.62; and RR  2.45, 95%
CI  1.13 to 5.30, respectively).
Table 4. Total Plasma Homocysteine Levels According to
Event Type at One-Year Follow-Up*
Homocysteine (mol/l)
p Value
Adverse
Event
No Adverse
Event
Death (from any cause) 14.1  2.5 9.6  4.3 0.004
MACE
Target lesion revascularization 10.7  4.4 9.5  4.3 0.02
Nonfatal myocardial infarction 11.2  3.4 9.6  4.3 0.18
Cardiac death 14.9  1.7 9.6  4.3 0.003
Any cardiac event 11.0  4.4 9.4  4.3 0.004
*Continuous variables are mean  SD. Homocysteine level differences between
patients with and those without adverse events were examined by the Mann-Whitney
U test.
MACE  major adverse cardiac events.
1773JACC Vol. 40, No. 10, 2002 Schnyder et al.
November 20, 2002:1769–76 Homocysteine and Outcome After Coronary Angioplasty
independent of other known risk factors for impaired
outcome after PCI and could be reproduced in subgroups of
patients stratified according to the traditional cardiovascular
risk factors, clearly demarcating the effect of elevated ho-
mocysteine levels from those very factors.
The pathogenesis of homocysteine-induced vascular in-
jury and its possible role with regard to the adverse outcome
after PCI are not clearly understood. Nevertheless, increas-
ing evidence suggests that the primary mechanism may be
oxidative-endothelial injury and dysfunction (15,21). Ho-
mocysteine is rapidly auto-oxidized when added to plasma,
forming potent reactive oxygen species, including superox-
ide and hydrogen peroxide (22). Auto-oxidation of homo-
cysteine not only increases the generation of hydrogen
peroxide but also decreases its degradation by impairing
intracellular endothelial antioxidant enzymes, thus render-
ing nitric oxide more susceptible to oxidative inactivation
(23). Furthermore, homocysteine auto-oxidation has been
shown to promote lipid peroxidation (24), which enhances
platelet-derived growth factor gene expression and receptor
formation in vascular smooth muscle cell (25). Finally,
elevated homocysteine levels may enhance vascular constric-
tive remodeling by inactivating peroxisome proliferator-
activated receptors in endothelial cells and smooth muscle
cells (26). All this ultimately increases smooth muscle cells
proliferation and chemoattraction (27). Therefore,
homocysteine-induced endothelial dysfunction, lipid per-
oxidation, and inactivation of peroxisome proliferator-
activated receptors may promote smooth muscle cell prolif-
eration, extracellular matrix formation, and ultimately
increase the need for repeat TLR and overall MACE after
PCI. Our findings of a substantial increase in RR of
composite end points between extreme homocysteine quar-
tiles in patients with higher LDL cholesterol levels and of
only a modest increase with lower LDL cholesterol levels
support this possible mechanism. Furthermore, homocys-
teine levels have been inversely associated with the devel-
opment of collateral coronary circulation (28) and have been
shown to alter the physiologic endothelial antithrombotic
phenotype through interaction with coagulation factor V
(29), protein C (30), tissue plasminogen (31), and tissue
factor activity (32), which may trigger acute or late throm-
boses. This is supported by our findings of an increased rate
of nonfatal MI and a higher mortality among patients with
homocysteine levels in the highest quartile.
A critical question is whether the association of homo-
cysteine levels with the outcome after PCI is causative. In
the present study, plasma homocysteine was significantly
correlated with age, serum creatinine, and HDL cholesterol,
as well as significantly associated with gender and previous
MI. Furthermore, the treatment of restenotic lesions, as
well as lesions in diabetics treated with oral hypoglycemics
were significantly associated with a worse outcome after
PCI. Adjustment for all these factors did not weaken the
predictive power of plasma homocysteine, suggesting an
independent association with the outcome after PCI. An-Ta
bl
e
5.
U
ni
va
ri
at
e
P
re
di
ct
or
s
of
E
nd
po
in
ts
by
C
ox
R
eg
re
ss
io
n
A
na
ly
si
s*
D
ea
th
C
ar
di
ac
D
ea
th
N
on
fa
ta
l
M
I
T
L
R
M
A
C
E
H
R
(9
5%
C
I)
p
H
R
(9
5%
C
I)
p
H
R
(9
5%
C
I)
p
H
R
(9
5%
C
I)
p
H
R
(9
5%
C
I)
p
H
om
oc
ys
te
in
e/

m
ol
/l
1.
18
(1
.0
7–
1.
29
)
0.
00
5
1.
20
(1
.0
8–
1.
33
)
0.
00
5
1.
07
(0
.9
7–
1.
18
)
0.
18
1.
06
(1
.0
1–
1.
10
)
0.
02
5
1.
07
(1
.0
2–
1.
11
)
0.
00
5
H
om
oc
ys
te
in
e/
qu
ar
til
e
—
†
—
†
0.
19
(0
.0
0–
0.
84
)
0.
04
0
0.
22
(0
.1
1–
0.
43
)
0.
00
8
0.
20
(0
.1
1–
0.
39
)
0.
00
2
D
ia
be
te
s
m
el
lit
us
2.
77
(0
.5
7–
5.
27
)
0.
17
2.
94
(0
.9
2–
5.
25
)
0.
08
1
2.
29
(0
.6
6–
5.
22
)
0.
16
2.
06
(1
.2
3–
3.
12
)
0.
00
8
2.
10
(1
.2
9–
3.
12
)
0.
00
5
R
es
te
no
tic
le
si
on
s
1.
90
(0
.2
5–
3.
92
)
0.
48
2.
53
(0
.3
1–
5.
01
)
0.
35
1.
09
(0
.1
5–
2.
39
)
0.
88
2.
49
(1
.4
2–
3.
72
)
0.
00
4
2.
34
(1
.3
4–
3.
49
)
0.
00
8
V
es
se
ld
ia
m
et
er
0.
99
(0
.3
8–
1.
59
)
0.
96
1.
05
(0
.6
7–
1.
43
)
0.
80
1.
04
(0
.8
3–
1.
27
)
0.
64
0.
78
(0
.5
7–
0.
99
)
0.
04
2
0.
81
(0
.6
2–
1.
00
)
0.
04
9
R
es
id
ua
lM
L
D
1.
39
(0
.2
9–
2.
50
)
0.
56
1.
60
(0
.3
3–
2.
86
)
0.
47
1.
38
(0
.5
4–
2.
21
)
0.
45
0.
74
(0
.5
0–
0.
96
)
0.
03
9
0.
77
(0
.5
7–
0.
97
)
0.
41
D
is
ea
se
d
ve
ss
el
s
0.
21
(0
.0
0–
0.
99
)
0.
03
4
0.
32
(0
.0
0–
0.
98
)
0.
02
9
0.
27
(0
.0
0–
0.
96
)
0.
02
1
0.
79
(0
.2
9–
1.
30
)
0.
36
0.
75
(0
.2
7–
1.
24
)
0.
25
E
je
ct
io
n
fr
ac
tio
n
0.
95
(0
.9
0–
0.
99
)
0.
04
9
0.
94
(0
.8
8–
0.
99
)
0.
02
3
0.
96
(0
.9
3–
1.
00
)
0.
06
8
0.
99
(0
.9
7–
1.
01
)
0.
47
0.
99
(0
.9
7–
1.
01
)
0.
26
*C
ox
re
gr
es
si
on
w
as
us
ed
,w
ith
en
te
ri
ng
of
on
ly
on
e
va
ri
ab
le
(S
ta
tV
ie
w
V
er
si
on
4.
5)
.T
he
fo
llo
w
in
g
va
ri
ab
le
s
w
er
e
te
st
ed
(y
es
/n
o)
un
le
ss
st
at
ed
ot
he
rw
is
e:
ag
e
(p
er
on
e-
ye
ar
in
cr
em
en
t)
;m
al
e
ge
nd
er
;s
m
ok
er
;d
ia
be
te
s
m
el
lit
us
tr
ea
te
d
w
ith
or
al
hy
po
gl
yc
em
ic
s;
sy
st
em
ic
hy
pe
rt
en
si
on
;h
yp
er
ch
ol
es
te
ro
le
m
ia
;h
is
to
ry
of
M
I;
hi
st
or
y
of
M
I
w
ith
in
th
e
la
st
si
x
m
on
th
s;
hi
st
or
y
of
pe
rc
ut
an
eo
us
co
ro
na
ry
in
te
rv
en
tio
n;
hi
st
or
y
of
co
ro
na
ry
ar
te
ry
by
pa
ss
gr
af
tin
g;
di
sc
ha
rg
e
th
er
ap
y:
st
at
in
s,

-b
lo
ck
er
s,
an
gi
ot
en
si
n-
co
nv
er
tin
g
en
zy
m
e
in
hi
bi
to
rs
,a
sp
ir
in
,a
de
no
si
ne
di
ph
os
ph
at
e
in
hi
bi
to
rs
;h
om
oc
ys
te
in
e
(p
er
1

m
ol
/l
in
cr
em
en
t)
;h
om
oc
ys
te
in
e
qu
ar
til
es
(1
st
,2
nd
vs
.3
rd
,4
th
);
cr
ea
tin
in
e
(p
er
0.
1
m
g/
dl
in
cr
em
en
t)
;t
ot
al
ch
ol
es
te
ro
l,
L
D
L
ch
ol
es
te
ro
l,
tr
ig
ly
ce
ri
de
s
(p
er
5
m
g/
dl
in
cr
em
en
t)
;h
ig
h-
de
ns
ity
lip
op
ro
te
in
ch
ol
es
te
ro
l(
pe
r
1
m
g/
dl
in
cr
em
en
t)
;l
es
io
n
lo
ca
tio
n
on
le
ft
an
te
ri
or
de
sc
en
di
ng
co
ro
na
ry
ar
te
ry
;n
um
be
r
of
tr
ea
te
d
st
en
os
es
(o
ne
:y
es
/n
o)
;l
es
io
n
le
ng
th
(p
er
1-
m
m
in
cr
em
en
t)
;r
es
te
no
tic
le
si
on
s;
us
e
of
st
en
t;
us
e
of
gl
yc
op
ro
te
in
II
b/
II
Ia
in
hi
bi
to
rs
;v
es
se
ld
ia
m
et
er
(p
er
0.
1-
m
m
in
cr
em
en
t)
;p
os
t-
pe
rc
ut
an
eo
us
co
ro
na
ry
in
te
rv
en
tio
n
M
L
D
(p
er
0.
1-
m
m
in
cr
em
en
t)
;n
um
be
r
of
di
se
as
ed
co
ro
na
ry
ve
ss
el
s
(o
ne
:y
es
/n
o
[
1
le
si
on
,
50
%
di
am
et
er
st
en
os
is
pe
r
ve
ss
el
])
;e
je
ct
io
n
fr
ac
tio
n
(p
er
10
%
in
cr
em
en
t)
.†
B
ec
au
se
of
an
ab
se
nc
e
of
de
at
h
in
pa
tie
nt
s
w
ith
ho
m
oc
ys
te
in
e
le
ve
ls
in
th
e
tw
o
lo
w
er
ho
m
oc
ys
te
in
e
qu
ar
til
es
,n
o
ha
za
rd
ra
tio
co
ul
d
be
co
m
pu
te
d.
C
I

co
nfi
de
nc
e
in
te
rv
al
;H
R

ha
za
rd
ra
tio
;M
A
C
E

m
aj
or
ad
ve
rs
e
ca
rd
ia
c
ev
en
ts
;M
I

m
yo
ca
rd
ia
li
nf
ar
ct
io
n;
M
L
D

m
in
im
al
lu
m
in
al
di
am
et
er
;T
L
R

ta
rg
et
le
si
on
re
va
sc
ul
ar
iz
at
io
n.
1774 Schnyder et al. JACC Vol. 40, No. 10, 2002
Homocysteine and Outcome After Coronary Angioplasty November 20, 2002:1769–76
giographic criteria such as larger vessel size and smaller
minimal luminal diameter, as well as the use of stents and
glycoprotein IIb/IIIa inhibitors have been shown to improve
outcome after coronary angioplasty (33–35). Nevertheless,
these angiographic characteristics and treatment modalities
were similar in all study subgroups and are, therefore,
unlikely to have affected our results.
Potential other limitations merit consideration. Having
included some patients with a history of MI within the last
six months may have increased homocysteine levels on
admission (36). Even though this inclusion may have
influenced absolute homocysteine levels, this should not
have affected our final results, given that blood samples were
drawn in a similar fashion for all study patients and rates of
recent (6 months) MI were comparable for all study
subgroups.
Overall, this study’s findings seem compelling, but do
they withstand the growing belief that atherosclerotic dis-
ease itself may elevate homocysteine levels, and that this
emerging cardiovascular risk factor is only a silent bystander
and should be considered a marker rather than a true
cardiovascular risk factor (19)? In our study, the association
between homocysteine levels and the outcome after PCI was
independent of the traditional cardiovascular risk factors.
Furthermore, the differences between the mechanism of
restenosis (recoil, remodeling, and excessive neointimal
hyperplasia) and the development of atherosclerotic lesions
are highlighted by the lack of correlation of the traditional
risk factors such as hypertension, smoking, and hypercho-
lesterolemia with the incidence of restenosis. Only diabetes
and elevated homocysteine levels influence restenosis, but
most importantly, independently from one another. Con-
cerns that elevated homocysteine levels are just a marker
rather than a risk factor, therefore, are unwarranted with
regard to restenosis. This independent relationship is fur-
ther emphasized by similar findings after carotid endarter-
ectomy (12,13) and, most importantly, by the recently
published benefit of homocysteine-lowering therapy on
angiographic restenosis (37).
In conclusion, with the exception of diabetes mellitus and
technical procedural considerations, elevated plasma homo-
cysteine seems to be the only known modifiable risk factor
influencing late outcome after successful coronary angio-
plasty.
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